Searchable abstracts of presentations at key conferences in endocrinology

ea0005p81 | Diabetes, Metabolism and Cardiovascular | BES2003

Effects of the 11beta hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in human obesity

Sandeep T , Andrew R , Homer N , Walker B

Inhibiting 11beta-hydroxysteroid dehydrogenase type 1 (11HSD1) has been proposed to prevent local regeneration of cortisol from cortisone, and thus enhance hepatic and adipose insulin sensitivity. In healthy men and patients with type 2 diabetes, the non-selective 11HSD inhibitor carbenoxolone enhances hepatic insulin sensitivity but, paradoxically, does not increase peripheral glucose disposal. In obesity, 11HSD1 activity and mRNA are increased in adipose biopsies. We tested ...

ea0003oc41 | Neuroendocrinology | BES2002

11beta-hydroxysteroid dehydrogenase type 1 (11beta HSD1) is expressed in human brain: inhibition with carbenoxolone improves cognitive function in healthy elderly men

Sandeep T , MacLullich A , Yau J , Noble J , Walker B , Seckl J

Elevated cortisol in Cushing's syndrome or ageing is associated with cognitive dysfunction. 11beta-HSD1 is expressed in rodent hippocampus and frontal cortex, regions important for cognition. In cultured rat hippocampal neurons, 11beta-HSD1 regenerates corticosterone from inert 11-dehydrocorticosterone and its inhibition by carbenoxolone is neuroprotective. 11beta-HSD1 knockout mice are protected against age-related cognitive dysfunction. We hypothesised that in elderly humans...

ea0009oc35 | Oral Communication 5: Thyroid | BES2005

Risk of second cancers among people with thyroid cancer - treatment effects or common aetiology?

Sandeep T , Strachan M , Reynolds R , Brewster D , Scelo G , Pukkala E , Hemminki K , Anderson A , Tracey E , Friis S , McBride M , Kee-Seng C , Pompe-Kirn V , Kliewer E , Tonita J , Jonasson J , Martos C , Boffetta P , Brennan P

BackgroundIncreasing incidence of thyroid cancer together with improved prognosis raises a concern regarding development of second primary cancers. Moreover, little is known about the incidence of thyroid cancer as a second primary neoplasm after other cancers.MethodsA cohort of 39002 people (356034.5 person years) with primary thyroid cancer was identified in 13 population-based cancer registries in Europe, ...